Plus Therapeutics Files S-1, Updates Financials

TL;DR

PLUS S-1 filed 6/7, showing updated financials & stock comp details. Check it out.

AI Summary

Plus Therapeutics, Inc. filed an S-1 form on June 7, 2024, detailing its financial status and business operations. The company, formerly known as Cytori Therapeutics, Inc. and Macropore Inc., is based in Austin, TX. The filing provides financial data for periods ending December 31, 2023, March 31, 2024, and earlier years, including details on stock-based compensation plans.

Why It Matters

This S-1 filing provides crucial updated financial information and operational details for Plus Therapeutics, Inc., which is essential for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carries risk.

Key Numbers

• 20240607 — Filing Date (Date the S-1 form was filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Filer
• CYTORI THERAPEUTICS, INC. (company) — Former Company Name
• MACROPORE INC (company) — Former Company Name
• AUSTIN, TX (location) — Business Address
• 0001193125-24-157500 (filing_id) — Accession Number

FAQ

Key Financial Figures

• $0 — 4,596 shares of common stock, par value $0.001, of Plus Therapeutics, Inc., a Dela
• $2.48 — sing sale price of our Common Stock was $2.48 per share. Investing in our common st
• $3.0 million — veral cancer targets. We have an active $3.0 million award from U.S. National Institutes of

Filing Documents

• d840996ds1.htm (S-1) — 2282KB
• d840996dex51.htm (EX-5.1) — 11KB
• d840996dex1015.htm (EX-10.15) — 4KB
• d840996dex231.htm (EX-23.1) — 2KB
• d840996dexfilingfees.htm (EX-FILING FEES) — 22KB
• g840996g01a00.jpg (GRAPHIC) — 43KB
• g840996g0606105124424.jpg (GRAPHIC) — 2KB
• 0001193125-24-157500.txt ( ) — 8593KB
• pstv-20240331.xsd (EX-101.SCH) — 57KB
• pstv-20240331_cal.xml (EX-101.CAL) — 45KB
• pstv-20240331_def.xml (EX-101.DEF) — 247KB
• pstv-20240331_lab.xml (EX-101.LAB) — 496KB
• pstv-20240331_pre.xml (EX-101.PRE) — 400KB
• d840996ds1_htm.xml (XML) — 1145KB

USE OF PROCEEDS

USE OF PROCEEDS 45 MARKET INFORMATION FOR COMMON STOCK 45 DIVIDEND POLICY 46

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 46

BUSINESS

BUSINESS 58 MANAGEMENT 64

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 71 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 77

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 79

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 82 SELLING STOCKHOLDERS 87 PLAN OF DISTRIBUTION 93 LEGAL MATTERS 96 EXPERTS 96 WHERE YOU CAN FIND ADDITIONAL INFORMATION 96 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING F-19 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. i ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling stockholders identified in this prospectus under the section entitled " Selling Stockholders ," from time to time, of up to an aggregate up to 10,774,596 shares of our common stock, consisting of: (i) 1,439,988 are shares of common stock, (ii) 2,151,544 shares are issuable upon the exercise of Pre-Funded Warrants, (iii) 3,591,532 shares are issuable upon the exercise of Series A Common Stock Warrants, and (iv) 3,591,532 shares are issuable upon the exercise of Series B Common Stock Warrants. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling stockholders, although we may receive cash from the exercise of the Warrants. You should rely only on the

View Full Filing

View this S-1 filing on SEC EDGAR